American Society of Addiction Medicine
American Society of Addiction Medicine
Lead: Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial
Lead: Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial
Lead: Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial
Tuesday 9th July 2024
Explore extended-release ketamine for depression, alcohol rehab's impact on cancer risk, and gaps in opioid use disorder treatment.
6 minutes
Informative
Hopeful
Supportive
Educational
Engaging
About this podcast
Author:
American Society of Addiction Medicine
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Family Recovery from Addiction
Nutritional Pathways to Recovery
Navigating Intimate Relationships
Links:
Visit site
Episodes:
131 (View all)
Do you want to link to this podcast?
Get the buttons here!Breakthroughs in Addiction Medicine: Ketamine Trials & Cancer Risks
Episode Overview
- Extended-release ketamine tablets show promise for treatment-resistant depression.
- Rehabilitation or abstinence significantly reduces cancer risk associated with alcohol dependence.
- Only half of those needing opioid use disorder treatment receive it.
- A third of community mental health facilities offer medications for OUD.
- Public awareness about MOUD needs improvement.
R107 tablets were effective, safe, and well-tolerated in patients with treatment-resistant depression.
Get ready for a deep dive into the latest advancements in addiction medicine with this episode of 'This Week in Addiction Medicine from ASAM'. Hosted by Zach Caruso, the episode kicks off with a fascinating discussion on extended-release ketamine tablets for treatment-resistant depression. This phase 2 clinical trial explores how oral administration of R-107 tablets can improve safety and tolerability for patients struggling with major depression.
It's a breakthrough that could change the way depression is treated, offering new hope to those who haven't responded to traditional therapies. Next up, the episode covers a significant study from France on alcohol rehabilitation and cancer risk. The findings are eye-opening: untreated alcohol dependence is strongly linked to several types of cancer, but rehabilitation and abstinence can reduce this risk by 40%. It's a stark reminder of the importance of seeking help for alcohol dependence.
The episode also highlights a CDC report on opioid use disorder (OUD) in the U.S., revealing that only about half of those needing treatment actually receive it. The discussion underscores the need for increased awareness and support for medication-assisted treatment. In another segment, you'll hear about the availability of medications for OUD in community mental health facilities.
Despite high rates of OUD among people with co-occurring mental health disorders, only a third of these facilities offer the necessary medications, indicating a critical gap in care. The episode wraps up with a look at public knowledge about opioid use disorder treatment in primary care and the promising results from a study on methamphetamine use reduction with naltrexone and bupropion.
Plus, there's a touching tribute to First Lady Betty Ford, who broke barriers by publicly discussing her battles with breast cancer and substance use disorder. This episode is packed with valuable information and compelling stories that highlight both the challenges and progress in addiction medicine. Don't miss out on these important updates that could impact your understanding of addiction treatment.